Zacks Investment Research lowered shares of Sienna Biopharmaceuticals (NASDAQ:SNNA) from a buy rating to a hold rating in a research note issued to investors on Wednesday morning.
According to Zacks, “Sienna Biopharmaceuticals Inc. is a medical dermatology and aesthetics company. It provides products for inflammatory skin diseases, tissue injury and unwanted light-pigmented hair reduction. The company operates primarily in the United States and Italy. Sienna Biopharmaceuticals Inc. is based in Westlake Village, United States. “
Several other analysts have also weighed in on SNNA. Cowen set a $45.00 price objective on Sienna Biopharmaceuticals and gave the company a buy rating in a report on Monday, December 3rd. BMO Capital Markets lowered their price objective on Sienna Biopharmaceuticals from $27.00 to $17.00 and set an outperform rating for the company in a report on Tuesday, December 4th. Finally, ValuEngine lowered Sienna Biopharmaceuticals from a buy rating to a hold rating in a report on Thursday, January 24th.
Sienna Biopharmaceuticals (NASDAQ:SNNA) last announced its quarterly earnings data on Thursday, March 14th. The company reported ($0.93) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.83) by ($0.10). Equities research analysts anticipate that Sienna Biopharmaceuticals will post -0.99 earnings per share for the current year.
Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc increased its holdings in Sienna Biopharmaceuticals by 11.2% in the third quarter. Vanguard Group Inc now owns 667,819 shares of the company’s stock valued at $9,897,000 after buying an additional 67,240 shares during the last quarter. FMR LLC grew its holdings in shares of Sienna Biopharmaceuticals by 0.3% during the third quarter. FMR LLC now owns 3,119,969 shares of the company’s stock valued at $46,238,000 after purchasing an additional 10,109 shares during the last quarter. Partner Fund Management L.P. grew its holdings in shares of Sienna Biopharmaceuticals by 1.6% during the third quarter. Partner Fund Management L.P. now owns 1,576,311 shares of the company’s stock valued at $23,361,000 after purchasing an additional 25,018 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Sienna Biopharmaceuticals by 11.2% during the third quarter. Vanguard Group Inc. now owns 667,819 shares of the company’s stock valued at $9,897,000 after purchasing an additional 67,240 shares during the last quarter. Finally, Jane Street Group LLC bought a new position in shares of Sienna Biopharmaceuticals during the third quarter valued at approximately $182,000. 43.95% of the stock is owned by hedge funds and other institutional investors.
Sienna Biopharmaceuticals Company Profile
Sienna Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of topical products in medical dermatology and aesthetics. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of pruritus or itch associated with psoriasis, as well as for psoriasis; and SNA-125, a topical janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus.
Featured Article: How do investors use RSI to grade stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sienna Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.